King's College London

Research portal

PharmacoEconomics, ‎1170-7690

Journal

  1. The Societal Cost of Schizophrenia: An Updated Systematic Review of Cost-of-Illness Studies

    Lin, C., Zhang, X. & Jin, H., 21 Nov 2022, In: PharmacoEconomics.

    Research output: Contribution to journalReview articlepeer-review

  2. Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study

    Pennington, B., Alshreef, A., Flight, L., Metry, A., Poku, E., Hykin, P., Sivaprasad, S., Prevost, A. T., Vasconcelos, J. C., Murphy, C., Kelly, J., Yang, Y., Lotery, A., Williams, M. & Brazier, J., Aug 2021, In: PharmacoEconomics. 39, 8, p. 913-927 15 p.

    Research output: Contribution to journalArticlepeer-review

  3. Overview and use of tools for selecting modelling techniques in health economic studies

    Jin, H., Robinson, S., Shang, W., Achilla, E., Aceituno Farias, D. & Byford, S., Jul 2021, In: PharmacoEconomics. 39, 7, p. 757-770 14 p.

    Research output: Contribution to journalReview articlepeer-review

  4. Cost-Effectiveness of Erenumab for the Preventive Treatment of Migraine in Patients with Prior Treatment Failures in Sweden

    Mahon, R., Lang, A., Vo, P., Huels, J., Cooney, P., Danyliv, A., Vudumula, U., Vadapalle, S., Maniyar, F. & Goadsby, P. J., Mar 2021, In: PharmacoEconomics. 39, 3, p. 357-372 16 p.

    Research output: Contribution to journalArticlepeer-review

  5. A Systematic Review of Economic Models Across the Entire Schizophrenia Pathway

    Jin, H., Tappenden, P., Robinson, S., Achilla, E., Maccabe, J., Aceituno Farias, D. & Byford, S., 6 Mar 2020, In: PharmacoEconomics. 38, 6, p. 537-555 19 p.

    Research output: Contribution to journalReview articlepeer-review

  6. Correction to: Are Quality-Adjusted Life Years a Good Proxy Measure of Individual Capabilities?

    Mitchell, P. M., Venkatapuram, S., Richardson, J., Iezzi, A. & Coast, J., Jul 2019, In: PharmacoEconomics. 37, 7, p. 969

    Research output: Contribution to journalComment/debate

  7. Does Non-Adherence Increase Treatment Costs in Schizophrenia?

    Pennington, M. & McCrone, P., 26 Apr 2018, (E-pub ahead of print) In: PharmacoEconomics. p. 1-15 15 p.

    Research output: Contribution to journalArticlepeer-review

  8. The Future of Precision Medicine: Potential Impacts for Health Technology Assessment

    Chalkidou, A., 2018, In: PharmacoEconomics. p. 1-13

    Research output: Contribution to journalArticlepeer-review

  9. Are Quality-Adjusted Life Years a Good Proxy Measure of Individual Capabilities?

    Mitchell, P. M., Venkatapuram, S., Richardson, J., Iezzi, A. & Coast, J., Jun 2017, In: PharmacoEconomics. 35, 6, p. 637-646

    Research output: Contribution to journalArticlepeer-review

  10. The Cost of Relapse in Schizophrenia

    Pennington, M. & McCrone, P., 22 May 2017, (E-pub ahead of print) In: PharmacoEconomics. p. 1-16 16 p.

    Research output: Contribution to journalArticlepeer-review

  11. Economic Evaluation of Mental Health Interventions: A Guide to Costing Approaches

    Shearer, J. D., McCrone, P. R. & Romeo, R., Dec 2016, In: PharmacoEconomics. 34, 7, p. 651-664

    Research output: Contribution to journalArticlepeer-review

  12. The Societal Cost of Schizophrenia: A Systematic Review

    Jin, H. & Mosweu, I. P., 24 Aug 2016, In: PharmacoEconomics.

    Research output: Contribution to journalArticlepeer-review

  13. Cost-of-illness studies for bipolar disorder: systematic review of international studies

    Jin, H. & McCrone, P. R., Apr 2015, In: PharmacoEconomics. 33, 4, p. 341-353 13 p.

    Research output: Contribution to journalArticlepeer-review

  14. Biological therapies for the treatment of severe psoriasis in patients with previous exposure to biological therapy: a cost-effectiveness analysis

    Sawyer, L. M., Wonderling, D., Jackson, K., Murphy, R., Samarasekera, E. J. & Smith, C. H., Feb 2015, In: PharmacoEconomics. 33, 2, p. 163-77 15 p.

    Research output: Contribution to journalArticlepeer-review

  15. On the use and interpretation of quantile regression in quality-of-life research

    Koeser, L. & McCrone, P., Feb 2014, In: PharmacoEconomics. 32, 2, p. 225-227 3 p.

    Research output: Contribution to journalArticlepeer-review

  16. Cost Effectiveness of Oromucosal Cannabis-Based Medicine (Sativex®) for Spasticity in Multiple Sclerosis

    Lu, L., Pearce, H., Roome, C., Shearer, J., Lang, I. A. & Stein, K., 1 Dec 2012, In: PharmacoEconomics. 30, 12, p. 1157-1171 15 p.

    Research output: Contribution to journalArticlepeer-review

  17. Impact of Treatment Success on Health Service Use and Cost in Depression Longitudinal Database Analysis

    Byford, S., Barrett, B., Despiegel, N. & Wade, A., 1 Feb 2011, In: PharmacoEconomics. 29, 2, p. 157 - 170 14 p.

    Research output: Contribution to journalArticlepeer-review

  18. Cost Effectiveness of Etoricoxib versus Celecoxib and Non-Selective NSAIDS in the Treatment of Ankylosing Spondylitis

    Jansen, J. P., Gaugris, S., Choy, E. H., Ostor, A., Nash, J. T. & Stam, W., 2010, In: PharmacoEconomics. 28, 4, p. 323 - 344 22 p.

    Research output: Contribution to journalArticlepeer-review

  19. Cost effectiveness of leukotriene receptor antagonists versus inhaled corticosteroids for initial asthma controller therapy: a pragmatic trial.

    EC, W., EJ, S., SD, M., L, S., A, B., J, M., HM, M., EF, J., JG, A., S, W., D, F., RF, G., I, H., EV, H. & D, P., 2010, In: PharmacoEconomics.

    Research output: Contribution to journalArticlepeer-review

  20. Cost effectiveness of leukotriene receptor antagonists versus long-acting beta-2 agonists as add-on therapy to inhaled corticosteroids for asthma: a pragmatic trial

    Wilson, E. C. F., Price, D., Musgrave, S. D., Sims, E. J., Shepstone, L., Murdoch, J., Mugford, H. M., Blyth, A., Juniper, E. F., Ayres, J. G., Wolfe, S., Freeman, D., Gilbert, R. F. T., Hillyer, E. V. & Harvey, I., 2010, In: PharmacoEconomics. 28, 7, p. 597-608 12 p.

    Research output: Contribution to journalArticlepeer-review

  21. The Cost of Relapse for Patients with a Manic/Mixed Episode of Bipolar Disorder in the EMBLEM Study

    Hong, J., Reed, C., Novick, D., Maria Haro, J., Windmeijer, F. & Knapp, M., 2010, In: PharmacoEconomics. 28, 7, p. 555 - 566 12 p.

    Research output: Contribution to journalLiterature reviewpeer-review

  22. Multiple sclerosis in the UK

    McCrone, P., Heslin, M., Knapp, M., Bull, P. & Thompson, A., Oct 2008, In: PharmacoEconomics. 26, 10, p. 847-860 14 p.

    Research output: Contribution to journalArticlepeer-review

  23. Cost-utility analysis of treatment with olanzapine compared to other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study

    SOHO Study Group, Apr 2008, In: PharmacoEconomics. 26, 4, p. 341 - 358 18 p.

    Research output: Contribution to journalArticlepeer-review

  24. Modelling the treated course of schizophrenia: a development of a discrete event simulation model

    Heeg, B., Buskens, E., Knapp, M., van Aalst, G., Dries, P., de Haan, L. & van Hout, B., 2005, In: PharmacoEconomics. 23, p. 17 - 33 17 p.

    Research output: Contribution to journalArticlepeer-review

  25. Pursuit of optimal outcomes in rheumatoid arthritis

    Scott, D. L., 2004, In: PharmacoEconomics. 22, 2, p. 13 - 26 14 p.

    Research output: Contribution to journalLiterature reviewpeer-review

  26. Heartburn in patients with gastro-oesophageal reflux disease in Germany and Sweden - A study on patients burden of disease

    Jones, R., Horbach, S., Sander, P. & Ryden-Bergsten, T., 2003, In: PharmacoEconomics. 21, 15, p. 1091 - 1102 12 p.

    Research output: Contribution to journalArticlepeer-review

  27. The Economics of screening and treatment in type 2 diabetes mellitus

    Raikou, M. (ed.) & McGuire, A. (ed.), 2003, In: PharmacoEconomics. 6, 8, p. S64 - S73 22 p.

    Research output: Contribution to journalArticlepeer-review

  28. The economic burden of stroke in the United Kingdom

    Youman, P., Wilson, K., Harraf, F. & Kalra, L., 2003, In: PharmacoEconomics. 21, SUPPL. 1, p. 43 - 50 8 p.

    Research output: Contribution to journalArticlepeer-review

  29. Common errors and controversies in pharmacoeconomic analyses

    Byford, S. & Palmer, S., 1998, In: PharmacoEconomics. 13, 6, p. 659 - 666 8 p.

    Research output: Contribution to journalArticlepeer-review

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454